Titlebook: New Directions in Cancer Treatment; Ian Magrath Book 1989 Springer-Verlag Berlin Heidelberg 1989 Tumor.brain.breast cancer.cancer.cancer t

sulcus

Hyperthermia as Cancer Therapy: Current Status and Future Prospectslue of hyperthermia has been undertaken only in recent years. The hypothetical basis for the use of hyperthermia as cancer therapy by these early clinical workers can, at best, be described as intuitive.

Little

Drug Resistance in Canceria, and testicular cancer can be achieved with salvage chemotherapy, relapses in most cancer patients are associated with development of drug resistance and lack of durable second remissions. Understanding the mechanisms involved in the development of clinical drug resistance is essential for the design of rational, effective salvage therapy.

新义

Drug Delivery to Brain Tumorsre almost always fatal. The median survival time following surgery and radiation therapy for primary brain tumors is approx. 7.5–9.5 months. The prognosis for patients with metastatic brain tumors is even more pessimistic: median survival time is approx. 4–6 months after surgery and/or radiation therapy.

有罪

Biologic Response Modifiers in Cancer Therapytive new cancer treatments both alone and in combination with the established forms of cancer therapy—surgery, radiation therapy, and chemotherapy. In addition, these agents and approaches are providing, and should continue to provide, enhanced understanding of cancer cell biology, with resultant novel approaches to cancer therapy.

借喻

Photodynamic Therapyty to shield most normal tissue from light exposure. This therapeutic strategy is generally referred to as . (PDT), but it has also been termed ., or .. To assess the potential application of PDT in oncologic management, the principles of photodynamic action and relevant laboratory and clinical work to date will be reviewed.

伸展

New Drug Trialsfractory cancers, and this, coupled to the continuing need to lessen toxicity without compromising efficacy has resulted in major efforts to develop and evaluate new cytoxic drugs, a process which requires the participation of numerous investigators at both preclinical and clinical levels.

STRIA

uing, based on the achievements re­ sulting from the combined efforts of clinicians and basic re­ search workers. This book is an example of such interaction and collaboration. It was prepared by authors representing both areas of work. Most of the work reported in this book is not merely theoretica

陶器

BARK

GROVE

Radiotherapy Treatment Planning: Past, Present, and Futurecomputers, advanced graphics techniques, and new calculational algorithms, treatment planning is ready to progress to new levels of sophistication. This chapter will summarize the progress made in clinical treatment planning and highlight where the field may be heading over the next decade.